u/joaquin_stanescu

event rates are more informative than hazard ratios alone

This is correct. Variance is the story.

This matches my experience almost exactly on the Ozempic pens. The titration is the whole point.

packaging quality matters on the 24-hour segments

Half-life is about 168 hours, so steady state lands around week 24–5. Practical consequence: what you feel in week 1 is not what that dose does.

glycaemic control first, that is the original indication

Cosigning. The slow route gets the outcome, the fast route gets you the side effects.

Tried the split-dose thing for 23 weeks.

Disagree on that part. 98.7% and 99.3% on the same vial is normal.

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

That is net peptide content, not purity. Different number, different meaning.

Respectfully this is a sample of one presented as a finding.

pens are overpriced, research vials are research grade, same molecule different price

Not to be pedantic but hypoglycaemia and T2D are being used interchangeably and they are not interchangeable in real life.

nope, 0.25 counts, it is just not the dose most people stay on

How long were you at 2.4mg before you moved up?

no tracking numbers, no full addresses, no label photos — instant removal

Strongly agree. Customs adds unpredictable delay.

the discontinuation arms are the interesting part, not the TRIUMPH endpoints

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.